169 filings
Page 2 of 9
8-K
o33k6t62mbkov96jwzo
13 Jul 22
Other Events
4:14pm
8-K
jvndgyjrte7u5qdu
5 Jul 22
Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
8:25am
8-K
g1cbi
14 Jun 22
Submission of Matters to a Vote of Security Holders
4:21pm
8-K
6prmlbkwlknqqo3xh
9 May 22
Precigen Reports First Quarter 2022 Financial Results and Business Updates
4:14pm
8-K
vamrufi84jow7d g6q
1 Mar 22
Precigen Reports Fourth Quarter and Full Year 2021 Financial Results
8:14am
8-K
72e g6sod
4 Nov 21
Precigen Achieves Significant Clinical Progress for UltraCAR-TĀ® and AdenoVerseā¢ Therapies
9:29am
8-K
2uk5w 5iltgj1cdg50bj
12 Oct 21
Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer
8:10am
8-K
819qwfweuvbr c7
9 Aug 21
Precigen Reports Second Quarter and First Half 2021 Financial Results
4:03pm
8-K
e90sejbk jj
15 Jun 21
Submission of Matters to a Vote of Security Holders
4:21pm
8-K
2yfta11s
28 May 21
Departure of Directors or Certain Officers
6:12am
8-K
l87v2 ymiuk7qgvl23
10 May 21
Precigen Reports First Quarter 2021 Financial Results
4:44pm
8-K
q9xfqupqp9buto
30 Mar 21
Precigen Announces Departure of Chief Financial Officer
12:00am
8-K
mw39i
1 Mar 21
Precigen Reports Fourth Quarter and Full Year 2020 Financial Results
4:18pm
8-K
u4n8catnyz3
26 Jan 21
Entry into a Material Definitive Agreement
4:13pm
8-K
q4ruvp96 k8aj9ueg3ai
13 Jan 21
Regulation FD Disclosure
4:32pm
8-K
nlbrdl
2 Dec 20
Unregistered Sales of Equity Securities
5:00pm
8-K
oa9a5q97
9 Nov 20
Precigen Reports Third Quarter 2020 and Year-to-Date Financial Results
8:14am
8-K
gezbz3pnj t6
9 Oct 20
Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note
7:43am
8-K
r64xbfy
25 Sep 20
Other Events
4:17pm
8-K
73sd9
25 Sep 20
Unregistered Sales of Equity Securities
4:15pm